Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

th year running and the awards ceremony will take place on November 18, 2009 in London.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to have been shortlisted for both the Biotech Company of the Year and Licensing Deal of the Year awards at this prestigious awards event. The nominations are a testament to the significant achievements and progress ThromboGenics has made over the last year. The Company is now in the best position to achieve its aim of becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines. We are very proud to be nominated amongst some of the most successful companies in the industry, and look forward to the results in November."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About Scrip World Pharmaceutical
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Two champions of ... their sponsorship of an annual competition for middle and ... access to, innovative STEM study. The competition presents students ... Tests of Engineering Aptitude, Mathematics, and Sciences is ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... (Frankfurt Stock Exchange: EVT) today announced that Jörn,Aldag, President & CEO, ... Date: Tuesday, ... 11.45 am EST (05.45 pm CET/04.45 pm GMT) Location: ... will be available on the Evotec website at, http://www.evotec.com - ...
... . , ANN ARBOR, Mich.---A new energy-capturing knee ... a portable GPS locator, a cell phone, a motorized ... University of Michigan shows. , A report on the ... the journal Science. Authors include researchers from Simon Fraser ...
... BRISBANE, Calif., Feb. 7 InterMune, Inc.,(Nasdaq: ITMN ) ... ended December 31, 2007. The company also provided 2008,financial guidance ... the Fourth Quarter 2007, InterMune reported a net loss ... per share, compared with a net loss of $21.5 million, ...
Cached Biology Technology:Knee brace generates electricity from walking 2InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 2InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 3InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 4InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 5InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 6InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 7InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 8InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 9InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 10InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 11
(Date:4/17/2014)... University (ANU), have developed a new way to ... the past 5.3 million years., The findings will ... ages over the past two million years, and ... levels, global temperatures and sea levels., The team ... the National Oceanography Centre (NOC) in the United ...
(Date:4/16/2014)... species of yellow-shouldered bats have been unearthed by scientists at the ... History and described in the open access journal ZooKeys ... are part of a recent discovery of three bats hidden ... to be officially announced. , Up until recently the genus ...
(Date:4/16/2014)... Doucet of the Centre INRSInstitut Armand-Frappier has just received a ... the amount of nearly US$600,000. The 5-year grant is to ... RNases and to explore their biomedical potential in the field ... , "Receiving a grant at this level is an ...
Breaking Biology News(10 mins):Ancient sea-levels give new clues on ice ages 2Two new species of yellow-shouldered bats endemic to the Neotropics 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2
... Embryonic stem cells, prized for their astonishing ability to apparently ... their identities in part by interacting with their surroundings - ... laboratory dish, University of Florida scientists report. , Using an ... McKnight Brain Institute have begun to answer one of the ...
... fact, beneficial microbes could represent the future of medicine, ... in humans and animals from diarrhea and eczema to ... released by the American Academy of Microbiology, Probiotic Microbes: ... used to treat a range of clinical conditions that ...
... have discovered a new gene that could lead to ... diabetes. , The gene, called SLIRP, was discovered by ... Research's (WAIMR) Laboratory for Cancer Medicine, led by Professor ... at Baylor College of Medicine in Texas. , "When ...
Cached Biology News:Birds going extinct faster due to human activities 2Birds going extinct faster due to human activities 3Report focuses on the role good microbes play in future medicine 2Gene discovery opens door to tackling disease 2
... protein ribonuclease inhibitor that noncovalently binds and inactivates ... seen with RNase 1, T1, T2, H, U1, ... placental ribonuclease inhibitor in that it has a ... release active RNase in the absence of DTT ...
... (Chemical Inkjet Printer) is a revolutionary ... and Protein Macroarray Analysis, developed in ... The strategy compliments established protocols in ... the proteins isoelectric point and apparent ...
... The BIOLASE Core Kit ... to perform polymerase assays on ... templates. In addition to dNTPs, ... on our widely used BIOLASE ...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
Biology Products: